



Washington State Health Care Authority
Prescription Drug Program

1511 3rd Ave Suite 523 • Seattle, Washington 98101
206-521-2029 • www.hca.wa.gov/pdp

April 25, 2016

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority (Medicaid/Uniform Medical Plan) and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective June 1, 2016:

Diabetes – Long-Acting Insulins reviewed 12/15/2015		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
insulin glargine	Lantus [®] injection	No	Yes	Yes
	Lantus Solostar [®] injectable pen	No	Yes	Yes
The effect of this recommendation is to add the Long-Acting Insulin drug class to the PDL and to make Lantus [®] and Lantus Solostar [®] preferred on the PDL.				

PCSK-9 Inhibitors reviewed 12/16/2015		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
evolocumab	Repatha [®] injection	No	Yes	Yes
	Repatha Sureclick [®] autoinjector	No	Yes	Yes
The effect of this recommendation is to add the PCSK-9 Inhibitor drug class to the PDL and to make Repatha [®] and Repatha Sureclick [®] preferred on the PDL.				

Each agency will use the common PDL according to its benefit structure. You may view the current PDL at: <http://www.hca.wa.gov/pdp/Documents/washingtonpdl.pdf>.

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

A handwritten signature in black ink that reads "Ray Hanley". The signature is written in a cursive style with a large initial "R" and a long, sweeping underline.

Ray Hanley
Prescription Drug Programs Director
Washington State Health Care Authority